Now live: Pro — the full 13F research suite for serious investorsSee pricing →
BOONE CAPITAL MANAGEMENT LLC

Q3 2023 · 13F-HR

BOONE CAPITAL MANAGEMENT LLCholdings as filed

Filed 2023-11-14 · accession 0001214659-23-015115

$317.0M
Reported value
13
Positions
2023-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
91529Y106UNMUNUM GROUP$42.7M13.5%867,565CommonSOLE
125523100CITHE CIGNA GROUP$37.2M11.7%129,917CommonSOLE
60855R100MOHMOLINA HEALTHCARE INC$37.1M11.7%113,178CommonSOLE
235851102DHRDANAHER CORPORATION$32.0M10.1%129,163CommonSOLE
194014502ENOVENOVIS CORPORATION$26.5M8.36%502,731CommonSOLE
031162100AMGNAMGEN INC$26.4M8.32%98,126CommonSOLE
09062X103BIIBBIOGEN INC$24.7M7.79%96,115CommonSOLE
379577208GMEDGLOBUS MED INC$21.3M6.71%428,452CommonSOLE
071813109BAXBAXTER INTL INC$17.7M5.59%469,405CommonSOLE
74766Q101QTRXQUANTERIX CORP$15.4M4.87%568,544CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$15.4M4.86%570,682CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS INC$12.3M3.89%389,791CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$8.3M2.61%313,381CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.